DexCom (NASDAQ:DXCM) Downgraded by StockNews.com

DexCom (NASDAQ:DXCM) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

DXCM has been the subject of a number of other reports. Morgan Stanley lifted their price target on DexCom from $101.00 to $122.00 and gave the stock an “equal weight” rating in a report on Monday, December 4th. Piper Sandler upped their target price on DexCom from $135.00 to $150.00 and gave the company an “overweight” rating in a research note on Tuesday, December 19th. Raymond James upped their price objective on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 23rd. Wells Fargo & Company increased their price target on DexCom from $110.00 to $136.00 and gave the company an “overweight” rating in a report on Wednesday, December 13th. Finally, Royal Bank of Canada assumed coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target for the company. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $136.67.

DexCom Trading Down 0.1 %

DXCM stock traded down $0.17 during midday trading on Tuesday, hitting $139.93. 3,057,444 shares of the company’s stock were exchanged, compared to its average volume of 3,144,022. DexCom has a 1-year low of $74.75 and a 1-year high of $142.00. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The business has a 50-day simple moving average of $124.72 and a two-hundred day simple moving average of $111.40. The stock has a market capitalization of $53.95 billion, a PE ratio of 106.82, a P/E/G ratio of 2.29 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.07. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. DexCom’s revenue was up 26.9% compared to the same quarter last year. During the same period last year, the business posted $0.34 earnings per share. On average, sell-side analysts predict that DexCom will post 1.76 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 4,137 shares of the firm’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $140.00, for a total transaction of $579,180.00. Following the sale, the executive vice president now directly owns 76,304 shares in the company, valued at $10,682,560. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Kevin R. Sayer sold 37,325 shares of DexCom stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $123.63, for a total transaction of $4,614,489.75. Following the completion of the sale, the chief executive officer now owns 362,841 shares of the company’s stock, valued at approximately $44,858,032.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sadie Stern sold 4,137 shares of DexCom stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $140.00, for a total transaction of $579,180.00. Following the completion of the sale, the executive vice president now owns 76,304 shares of the company’s stock, valued at approximately $10,682,560. The disclosure for this sale can be found here. Over the last three months, insiders have sold 183,635 shares of company stock worth $24,020,621. Company insiders own 0.41% of the company’s stock.

Hedge Funds Weigh In On DexCom

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bartlett & CO. Wealth Management LLC acquired a new position in shares of DexCom during the 4th quarter valued at $27,000. DSM Capital Partners LLC bought a new position in DexCom during the fourth quarter worth about $28,000. Valley National Advisers Inc. boosted its position in DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after purchasing an additional 103 shares during the period. Harbour Investments Inc. boosted its position in shares of DexCom by 55.6% in the third quarter. Harbour Investments Inc. now owns 336 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 120 shares during the period. Finally, Atlas Capital Advisors LLC bought a new position in shares of DexCom in the second quarter valued at approximately $33,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.